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https://doi.org/10.1016/j.jaci.2020.09.037Background: Systemic mastocytosis is a hematological disease
in which aberrant mast cells accumulate because of gain-of-
function mutations in the KIT receptor. Group 2 innate
lymphoid cells (ILC2s) are effector cells of type 2 immune
responses that also express KIT and colocalize with mast cells at
barrier tissue sites. In mouse models, mast cell-ILC2 crosstalk
can drive local inflammation. However, a possible role for ILC2s
in the pathophysiology of mastocytosis remains unexplored.
Objective: We sought to characterize circulating ILC2s in a
clinically diverse cohort of patients with mastocytosis.
Methods: We included 21 adults with systemic mastocytosis and
18 healthy controls. Peripheral blood ILC2 abundance and
phenotype were analyzed by flow cytometry and correlated to
clinical characteristics, including the presence of the D816V
KIT mutation.1
Abbreviations used
ILC2: Group 2 innate lymphoid cell
MPCM: Maculopapular cutaneous mastocytosis
SCF: Stem cell factor
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2 VAN DER PLOEG ET ALResults: ILC2 levels were significantly higher in D816V1
patients with mastocytosis compared with D816V2 patients or
healthy controls. We observed increased proportions of KIT1
ILC2s among patients with mastocytosis, regardless of D816V
status. Patients with skin involvement and itch showed the
highest levels of ILC2s, which was independent from atopy or
serum tryptase levels. Allele-specific quantitative PCR showed
that the vast majority of ILC2s did not carry the D816V
mutation.
Conclusions: Our findings suggest a role for ILC2s and
pathogenic ILC2-mast cell crosstalk in mastocytosis. We
hypothesize that a high cutaneous D816V1 mast cell burden
alters the skin microenvironment to induce chronic local ILC2
activation and their dissemination into the circulation.
Activated ILC2s could contribute to skin symptoms by
producing inflammatory mediators and by further augmenting
mast cell mediator release. (J Allergy Clin Immunol
2020;nnn:nnn-nnn.)
Key words: Mastocytosis, mast cell, innate lymphoid cell, ILC2,
KIT, itch, maculopapular cutaneous mastocytosisINTRODUCTION
Mastocytosis is a rare myeloproliferative disease in which
aberrant mast cells accumulate. Most adult patients have systemic
mastocytosis, which is defined by the involvement of at least 1
extracutaneous organ, most often the bone marrow.1 In 80% to
90% of patients with systemic mastocytosis, a somatic D816V
mutation is detected in the KIT receptor tyrosine kinase. Under
normal conditions, KIT requires binding of its ligand, stem cell
factor (SCF), to induce mast cell proliferation and survival.2
The D816V mutation leads to constitutive ligand-independent
activation of KIT signaling, resulting in uncontrolled mast cell
proliferation.2 Patients with systemic mastocytosis can suffer
from a wide variety of symptoms, including anaphylaxis, osteo-
porosis, itching, flushing, dyspepsia, diarrhea, fatigue, and psy-
chological symptoms, which can greatly reduce quality of life.3






Sex (male/female) 7/11 10/11
Age (y) 37.6 6 10.4)* 53.0 6
Serum tryptase (mg/L) NA 51.3 6
Neoplastic MC burden BM, n (%) NA 0.12 (0
Total IgE (U/mL) NA 26 6
Maculopapular cutaneous mastocytosis, % NA 81
Itch, % NA 66
Atopy, %§ 33.3 19
Anaphylaxis, % NA 23
Flushing, % NA 42
Osteoporosis, % NA 42
Diarrhea, % NA 38
BM, Bone marrow; MC, mast cell; NA, not applicable; NS, not significant.
*Continuous variables shown as mean 6 SD.
Controls were significantly younger than patients with mastocytosis (P 5 .001).
Neoplastic mast cell burden in the bone marrow was defined by aberrant expression of C
§Atopy in patients with mastocytosis was defined by clinical symptoms of asthma, rhinocon
specific IgE measurement. For healthy controls, atopy was defined as a history of allergiclevels of mediators released by mast cells such as histamine, tryp-
tase, eicosanoids, and proinflammatory cytokines. However, it re-
mains unclear why the type and severity of symptoms can vary so
greatly between individual patients. In patients with mastocyto-
sis, baseline serum tryptase and urine histamine levels do not
correlate with individual symptoms,4 suggesting that other cell
types might contribute to the pathophysiology of mastocytosis,
possibly through their activation by mast cell signals.
Innate lymphoid cells (ILCs) orchestrate immune responses at
mucosal surfaces in an antigen-independent manner. ILCs can be
grouped into various subtypes depending on the inflammatory
cytokines they produce, including group 2 ILCs (ILC2s), which
play a central role in type 2 immunity and in allergic
inflammatory disease.5 ILC2s and mast cells both reside at
barrier sites of the human body, such as the skin, gut, and
airways. Although ILC2s are largely tissue-resident, they can
also be detected in the circulation. Interestingly, like mast cells,
a subpopulation of ILC2s expresses KIT, and SCF can
augment ILC2 activation.6 In mice, mast cell-ILC2 crosstalk is
important not only to clear helminth infections but also to
drive local inflammation.7 However, whether such crosstalk is
also relevant in the context of mastocytosis remains to be
addressed.RESULTS AND DISCUSSION
Twenty-one patients with indolent systemic mastocytosis8 and
18 healthy controls were included in our study. Sixteen had a
detectable D816V KIT mutation in bone marrow samples. Pa-
tients’ characteristics are summarized in Table I. The
percentage of ILC2s was significantly increased in peripheralwith
(N 5 21)
D816V1
Patients (N 5 16)
D816V2




15.4 55.2 6 13.8 46 6 5.3 NS
72.2 62.9 6 78.7 11.8 6 34.6 .004
.13) 0.14 (0.10) 0.04 (0.03) NS
31 29 6 33 13 6 15 NS
.0 93.8 40 .008
.6 68.8 60 NS
.0 31.25 0 NS
.8 25 20 NS
.9 43.8 40 NS
.9 50 20 NS
.1 43.8 20 NS
D2 and/or CD25 as measured by flow cytometry.
junctivitis, and/or proven sensitization to pollen or house-dust mite by skin prick test or






































































































































































FIG 1. ILC2s are increased in peripheral blood of D816V1 patients with MC. A, Flow cytometry gating
strategy for ILC precursors, KIT1 ILC2s, and KIT2 ILC2s. B, Proportions of total ILC2s (left) and of KIT1
ILC2s (right) in peripheral blood of healthy controls (HCs) and D816V negative (D816V2), and D816V positive
(D816V1) patients with MC. C, Proportions of ILCPs in peripheral blood of HCs, D816V2, and D816V1
patients. D, KIT1 ILC2 proportions of total ILC2s in peripheral blood of HCs and patients with MC.
D816V2 patients are indicated by yellow symbols; D816V1 patients by red symbols. E, Proportions of
CCR41, CCR61, and ICOS1 ILC2s in peripheral blood of HCs and patients with MC. D816V2 patients are
indicated by yellow symbols; D816V1 patients by red symbols. ICOS, Inducible costimulator; ILCP, innate
lymphoid cell precursor; MC, mastocytosis. Data are shown as symbols for individual patients/controls,
together with bar graphs for mean values 1 SEM. Comparisons between groups were evaluated using a
Mann-Whitney U test; P < .05 was considered statistically significant.
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VAN DER PLOEG ET AL 3blood of patients with mastocytosis compared with healthy
controls, but only in patients carrying the D816V mutation
(Fig 1, A and B). Although the abundance of circulating KIT1
ILC precursors was similar across all groups (Fig 1, C), a
larger proportion of the circulating ILC2 compartment was
KIT1 in patients with mastocytosis, irrespective of D816V status
(Fig 1, D). Chemokine (CCR4, CCR6) and costimulatory
(inducible costimulator) receptor expression on ILC2s was
similar between groups (Fig 1, E). D816V1 patients showed
significantly higher serum tryptase levels (P 5 .004) and a
trend toward higher neoplastic bone marrow mast cell burden
(P 5 .136) compared with D816V2 patients (Table I). However,we did not detect a significant correlation between blood ILC2
levels and bone marrow neoplastic mast cell burden (Spearman
r 5 20.21; P 5 .435) or serum tryptase levels (Spearman
r 5 20.073; P 5 .752).
Although total CD41 T-cell levels did not differ, proportions of
CRTH21 TH2 cells, the functional counterparts of ILC2s
belonging to the adaptive immune system,5 were also
significantly increased in peripheral blood of patients with
mastocytosis compared with healthy controls (Fig 2).
However, we found no significant correlation between the






















































































FIG 2. CRTH21CD41 T cells are increased in peripheral blood of patients with MC. A, Flow cytometry gating
strategy for total CD41 and CRTH21CD41 T cells. B, Proportions of CD41 T cells in peripheral blood of
healthy controls (HCs) and D816V2 and D816V1 patients with MC. C, Proportions of CRTH21CD41 T cells
in peripheral blood of HCs and patients with MC. MC, Mastocytosis. Data are shown as symbols for
individual patients/controls, together with bar graphs for mean values 1 SEM. Comparisons between
groups were evaluated using a Mann-Whitney U test; P < .05 was considered statistically significant.
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4 VAN DER PLOEG ET ALWe next explored associations between circulating ILC2
populations and clinical symptoms in patients with mastocytosis.
Patients with maculopapular cutaneous mastocytosis (MPCM)
showed elevated levels of ILC2s as compared with healthy
controls and patients without MPCM (Fig 3, A). This is in line
with the high D816V prevalence (88.2%) in the MPCM1 group
and only a single D816V1 patient without MPCM. Additional
analysis using clinical data from our complete cohort of 263
adults with mastocytosis confirmed increased skin involvement
in D816V1 patients as compared with D816V2 patients: 73%
versus 42%, respectively (P 5 .002, chi-square test). Compared
with healthy controls, D816V1 patients who reported itch had
higher levels of ILC2s (Fig 3, B), irrespective of their KIT
expression status (Fig 3, C). Of note, D816V1 patients with or
without atopy showed similar levels of ILC2s, and we found no
significant correlation between serum IgE levels and ILC2
abundance (Spearman r 5 .007; P 5 .98) (Fig 4, A and B).
Furthermore, ILC2 abundance and KIT expression were not
associated with anaphylaxis, diarrhea, osteoporosis, or flushing,and we found no significant correlations with D816V allelic
burden in peripheral blood (P > .05). CRTH21 TH2 cell levels
were not specifically increased in patients with the D816V
mutation, MPCM, or itch (P > .05), emphasizing the specificity
of the association between ILC2s and D816V1 mastocytosis
with skin involvement.
To assess whether the altered ILC2 compartment in patients
with mastocytosis is linked to the occurrence of the D816V KIT
mutation in the ILC lineage, we performed allele-specific
quantitative PCR9 on isolated genomic DNA from ILC2s and
innate lymphoid cell precursors. Despite an approximately 1%
to 2% mutant allele detection sensitivity (see this article’s
Online Repository at www.jacionline.org), we could not detect
D816V allelic DNA in ILC2s or innate lymphoid cell precursors
(see Fig E1, A and B, in this article’s Online Repository at
www.jacionline.org), indicating that the D816V mutation is
absent or very rare in circulating ILCs.
Here, we describe, to our knowledge, the first explorative










































































































FIG 3. ILC2 levels and phenotype correlate with skin symptoms. A, Total (left) and KIT1 (right) ILC2
proportions in all patients with mastocytosis with or without MPCM. B, Total ILC2 proportions in D816V1
patients with mastocytosis with or without itch. C, KIT1 ILC2 proportions (left) and KIT positivity within
the ILC2 population (right) in D816V1 patients with mastocytosis with or without itch. D816V mutation
status is indicated for each individual patient (blue: D816V1, yellow: D816V2). HC, Healthy control. Data
are shown as symbols for individual patients/controls, with bar graphs for mean values 1 SEM.
Comparisons between groups were evaluated using a Mann-Whitney U test; P < .05 was considered
statistically significant.
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VAN DER PLOEG ET AL 5patients with mastocytosis. We found that patients with the
activating D816V KIT mutation in mast cells showed elevated
frequencies of circulating ILC2s compared with healthy controls
or D816V2 patients. The increased circulating ILC2 levels in
D816V1 patients were linked to the presence of MPCM and
itch. Together, our observations reveal positive associations
between ILC2 frequencies, the D816V mutation, and specifically
skin symptoms.
Because we could not detect the D816Vmutation in peripheral
blood ILCs, the increased ILC2 abundance in the circulation of
patients with mastocytosis with cutaneous symptoms is likely a
consequence of excessivemast cell activity in the bone marrow or
skin rather than a cell-intrinsic ILC2 defect. However, increased
bone marrow output of ILC2s appears an unlikely scenario,
because circulating ILC2 levels did not correlate with bone
marrow mast cell burden or serum tryptase levels. Hence, we
postulate that constitutive mediator release by D816V1 skin mast
cells, including inflammatory molecules such as IL-1b, TGFb,
and IL-33–activating proteases (eg, chymase and tryptase),10
could activate skin-resident ILC2s and create a favorable
microenvironment for recruiting circulating ILC2s (Fig 4, C).
Moreover, mast cell–derived prostaglandin D2 has previously
been shown to stimulate ILC2 cytokine production and migration
via CRTH2.11 Furthermore, soluble SCF levels are higher in le-
sional skin of patients with mastocytosis,12 potentially increasing
the local SCF availability for KIT1 ILC2s. Chronic ILC2activation could in turn contribute to a cutaneous cytokine milieu
that promotes inflammation, mast cell mediator release, and skin
symptoms—similar to mechanisms suggested for atopic derma-
titis.13 Prolonged stimulation of tissue ILC2s can trigger their sys-
temic dissemination,14 which can explain the increased ILC2
presence in the circulation in D816V1 mastocytosis.
Interestingly, KIT1 ILC2s express the skin-homing chemokine
receptor CCR10,6,15 implying that this ILC2 subset is capable
of efficiently migrating toward the skin (Fig 4, C). In line with
enhanced skin migration of KIT1 ILC2s in mastocytosis, we
observed that patients with frequent itch showed a reduced
relative proportion of KIT1 cells within their circulating ILC2
compartment compared with patients without itch.
In summary, we conclude that circulating ILC2s are elevated in
D816V1 mastocytosis and are associated with the presence of
MPCM and itch, providing a strong rationale for performing
in-depth studies into the role of ILC2s in the pathophysiology
of mastocytosis.
For detailed methods, please see the Methods section in this
article’s Online Repository at www.jacionline.org.
We thank R.W. Hendriks, P.M. van Hagen, and R. Gerth vanWijk (Erasmus
MC, Rotterdam) for insightful discussions, andM. van Nimwegen andM.J.W.
de Bruijn (Erasmus MC, Rotterdam) for their technical assistance. We thank
G.M. de Boer, G.J. Braunstahl, and G.A. Tramper (Franciscus Gasthuis &
Vlietland Hospital, Rotterdam) for inclusion of healthy control individuals.
FIG 4. ILC2 levels do not correlate with atopy status and the proposedmodel for pathological ILC2-mast cell
interplay in the skin of D816V1 patients with MC. A, Total ILC2 proportions in D816V1 patients with MC and
healthy control (HC) subjects with or without atopy. B, Scatter plot showing an absence of correlation
between total IgE levels (U/mL) and ILC2 abundance (Spearman r 5 .007; P 5 .98). Data are shown as
symbols for individual patients/controls, with bar graphs for mean values 1 SEM. Comparisons between
groups were evaluated using a Mann-Whitney U test; P < .05 was considered statistically significant.
C, Constitutive mediator release by D816V1 skin mast cells, including inflammatory molecules such as
IL-1b, TGFb, PGD2, and IL-33–activating proteases (eg, chymase and tryptase) activate skin-resident ILC2s
and create a favorable microenvironment for recruiting circulating ILC2s (ie, via CCR10). Elevated soluble
SCF levels further augment KIT1 ILC2 activation. Chronic ILC2 activation in turn contributes to an
inflammatory cutaneous cytokine milieu (eg, via production of IL-9) that further promotes mast cell activity
and skin symptoms but also triggers ILC2 dissemination into the circulation. Solid arrows denote activation
via indicated signaling molecules; dashed arrow indicate cleavage of IL-33 into mature active IL-33; striped
arrows depict cellular migration. MC, Mastocytosis; PGD2, prostaglandin D2.
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d Peripheral blood ILC2 abundance is increased in patients
with indolent systemic mastocytosis who carry the D816V
KIT mutation in mast cells.
d Although circulating KIT1 ILC2s are increased in masto-
cytosis, ILC2s do not appear to harbor the D816V
mutation.
d Elevated ILC2 levels correlate with skin symptoms such
as itch, but are independent from atopy status and serum
tryptase levels.
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METHODS
Subjects
Adult patients who fulfilled the World Health Organization criteriaE1 for
indolent systemic mastocytosis were recruited from the Erasmus MC
Mastocytosis Center outpatient clinic. Healthy controls were recruited by
the Franciscus Gasthuis & Vlietland hospital in Rotterdam. This study was
performed according to the latest Helsinki guidelines. All subjects provided
a written informed consent, and all experimental procedures were approved
by the Medical Ethical Committee of the Erasmus MC in Rotterdam, the
Netherlands.
Flowcytometry analysis and fluorescence assisted
cell sorting
PBMCs were isolated from whole blood by density gradient centrifugation
using Ficoll-PaqueTM PLUS (GE Healthcare Life Sciences, Eindhoven, The
Netherlands). PBMCs were subjected to extracellular staining with antibodies
for 60 minutes at 48C, and for 15 minutes at 48C with LIVE/DEAD Fixable
Green Dead Cell Stain Kit (Thermofisher, Breda, The Netherlands). Stainings
were performed with 5 to 10 million PBMCs to obtain a sufficient number of
ILCs. The following antibodies to human proteins were used (including
manufacturer, dilutions used, and clone numbers): From BioLegend (Am-
sterdam, The Netherlands): Peridinin chlorophyll protein–cyanine 5.5
(PerCP-Cy5.5)-conjugated anti-CCR4 (1:40, L291H4), Briliant violet (BV)
421-conjugated anti-CD117 (1:20, 104D2), fluorescein isothiocyanate
(FITC)-conjugated anti-CD94 (1:20, DX22), andAlexa Fluor 700–conjugated
anti-NKp46 (1:20,9E2). From Thermofisher: Allophycocyanin
(APC)-conjugated anti-CD127 (1:20, eBioRDR5), FITC-conjugated
anti-CD3 (1:100, UCHT1), anti-CD14 (1:200, 61D3), and phycoerythrin
(PE)-indotricarbocyanine (Cy)7-conjugated streptavidin (1:1000). From
Miltenyi Biotec (Leiden, The Netherlands): Biotinylated anti-CRTH2 (1:50,
BM16). From BD Biosciences (Vianen, The Netherlands): FITC-conjugated
anti-CD19 (1:300, HIB19), anti-CD16 (1:400, 3G8), anti-TCRgd (1:20, B1),
PE-conjugated anti-CCR6 (1:20, 11A9), BV650-conjugated anti–inducible
costimulator (1:20, DX29), BV605-conjugated anti-CD56 (1:50,
NCAM16.2), and BV785-conjugated anti-CD4 (1:30, SK3). For flowcytom-
etry analysis, data were acquired on an LSR II or a FACSymphony flow
cytometer using FACS Diva software 6.1 (BD Biosciences) and analyzed
using FlowJo 10 (BD Biosciences). We sorted approximately 2000 ILC2s
(Lineage2CD1271CRTH21) or innate lymphoid cell precursor (Line-
age2CD1271CD1171CRTH22) in 1.5 mL eppendorf tubes rinsed with
10% FCS for real-time quantitative D816V mutation detection PCR using a
FACSAria (BD Biosciences).
Real-time quantitative D816V mutation detection
PCR
Genomic DNA was isolated from sorted ILC2 and innate lymphoid cell
precursor fractions (with a FACSAria, see above) using the DNeasy Blood &
Tissue Kit (Qiagen) according to the manufacturer’s instructions. The
presence of KIT D816V mutant alleles was evaluated using a previously
describedE2 routine diagnostics real-time quantitative PCR assay that uses
wild-type and mutation-specific primer/probe sets. The D816V mutation
was deemed undetectable if cycle threshold values were greater than 38.
DNA from HMC1.2 cells was used as a control for the D816V mutant allele,
and DNA from peripheral blood buffy coats as control for the wild-type allele.
The quantitative range of the assay was controlled for by including a
standardized serial dilution of HMC1.2 or peripheral blood buffy coat
genomic DNA in the same run. Accurate detection of both alleles was
observed down to the 0.01% dilution (as indicated by the positive control
bars in Fig E1).
Tryptase and IgE measurements
Serum tryptase level was measured by fluoroenzymeimmunoassay
technology using the Phadia250 system (Thermo Fisher Scientific, Uppsala,
Sweden) according to the manufacturer’s instructions. Total serum IgE level
(U/mL) was also measured by fluoroenzymeimmunoassay on the Phadia 250
system using the ImmunoCAP Total IgE test (Thermo Fisher Scientific),
according to manufacturer’s instructions.
Immunophenotyping of neoplastic mast cells in
bone marrow
Flow cytometry immunophenotyping of mast cells from bone marrow
aspirate is performed routinely in our laboratory for diagnostic purposes, and
precisemethods have been previously described in great detail.E3 Briefly, bone
marrow aspirate is collected in heparin tubes and processed within 24 hours.
Erythrocytes are lysed using ammonium chloride after which leucocytes are
washed with PBS/BSA and resuspended at 63 107 cells/mL. Fifty microliter
of this suspension is stained (10 minutes at room temperature) using the
following antibodies: CD117-PE (104D2), CD45-PerCP (2D1), CD25-APC
(2A3), CD117-PE-Cy7 (104D2; custom conjugated), CD34-APC-Cy7
(8G12; custom conjugated) (all from BD Biosciences); CD2-FITC (T11),
CD2-PE (T11), CD33-PE (My9) (all from Beckman Coulter); and
CD117-APC (104D2; Dako Cytomation, Glostrup, Denmark). Subsequently,
cells are washed with PBS/BSA and resuspended in FACSFlow Solution (BD
Biosciences). Data are acquired using a FACSCalibur or FACS Canto B. Of
note, 1 3 106 cells are recorded per tube. Data are analyzed using FACS
Diva software. Mast cells are gated on the basis of strong CD117 expression
and subsequent gating is performed in the 6-color analysis using CD33
positivity and CD34 negativity. Neoplastic mast cells are CD2 and/or CD25
positive.
Statistical analysis
Depending on the type of variables, we used nonparametricMann-Whitney
U tests, chi-square tests, and Spearman correlation analyses to determine
statistical significance. IBM SPSS Statistics (25) and Prism Graphpad
software (8.0.2) were used for statistical analyses.
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FIG E1. Failure to detect D816V allelic DNA in genomic DNA isolated from circulating ILC2s or ILCPs. Shown
are cycle threshold (Ct) values from diagnostic quantitative PCR assays for the wild-type and D816V KIT
alleles on genomic DNA isolated from approximately 2000 sorted ILCPs (A) and ILC2s (B) of 6 patients with
mastocytosis with detectable D816V KIT alleles in bonemarrow samples. Serially diluted DNA from HMC1.2
cells was used as a positive control for the D816V mutant allele; DNA from peripheral blood buffy coats was
used as control for the wild-type allele. Internal controls (‘‘pos. ctrl’’) for both PCR assays (10% and 0.01%
dilutions) are indicated in the figure. The D816V mutation was deemed undetectable (‘‘ND’’) if Ct values
were greater than 38. Combining the number of input cells, the successful amplification of the 0.01%
dilution control, and the approximately 8 Ct remaining detection range, this experimental set up translates
to an approximately 1% to 2% mutant allele detection sensitivity. ILCP, Innate lymphoid cell precursor.
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